摘要
达普司他(Daprodustat,DAP)是一种新型口服低氧诱导因子脯氨酰羟化酶抑制剂(Hypoxiainducible factor prolyl hydroxylase inhibitor,HIF-PHI),可以稳定低氧诱导因子(Hypoxia-inducible factor,HIF),从而增加HIF所调控靶基因的转录与表达,发挥促进红细胞生成、提高血红蛋白水平以及影响铁代谢等作用。达普司他的适应证主要为血液透析和非血液透析依赖性慢性肾脏病患者的肾性贫血,具有良好的疗效和安全性。达普司他为肾性贫血患者群体提供了更高效、更安全的治疗选择,但其尚未在我国上市,临床应用前景值得期待。本文对达普司他治疗肾性贫血的研究进展进行综述。
Daprodustat is a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor(HIF-PHI),which can stabilize hypoxia-inducible factor(HIF),thereby increasing the transcription and expression of target genes regu‐lated by HIF,and exert the role of promoting erythropoiesis,increasing hemoglobin levels,and affecting iron metabo‐lism.The indications for daprodustat are mainly renal anemia in patients with hemodialysis and non-hemodialysis-dependent chronic kidney disease,and it has good therapeutic efficacy and safety.Daprodustat provides a more effi‐cient and safer treatment option for patients with renal anemia,but has not yet been listed on the market in China,and the prospect of its clinical application is promising.In this paper,the research progress of daprodustat in the treatment of renal anemia is reviewed.
作者
鲁远
罗琰琨
Lu Yuan;Luo Yankun(Department of Nephrology,Shanxi Provincial People's Hospital Affiliated to Shanxi Medical University,Taiyuan 030012,China)
出处
《实用药物与临床》
2025年第6期459-463,共5页
Practical Pharmacy and Clinical Remedies
基金
山西省科技计划项目(202103021224389)。
